Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 6/20 | 0.39 |
| ▸ | HTR2B | P41595 | 5/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | CDA | P32320 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23297036 | 0.98 | FPR2 (0.39) | FPR2HTR2CHTR2BNOS3NOS1 | |
| SCHEMBL23336150 | 0.89 | FPR2 (0.44) | FPR2HTR2CHTR2BTP53PARP1 | |
| SCHEMBL15447439 | 0.89 | FPR2 (0.44) | FPR2HTR2CHTR2BTP53PARP1 | |
| SCHEMBL18780594 | 0.89 | FPR2 (0.44) | FPR2HTR2CHTR2BTP53PARP1 | |
| Hydrochloric Acid SCHEMBL23296576 | 0.87 | FPR2 (0.43) | FPR2HTR2CHTR2BTP53PARP1 | |
| Hydrochloric Acid SCHEMBL23296920 | 0.87 | FPR2 (0.43) | FPR2HTR2CHTR2BTP53PARP1 | |
| Hydrochloric Acid SCHEMBL23296977 | 0.87 | FPR2 (0.43) | FPR2HTR2CHTR2BTP53PARP1 | |
| SCHEMBL5380207 | 0.79 | HTR2C (0.39) | FPR2HTR2CHTR2BNOS3NOS1 | |
| SCHEMBL14918285 | 0.79 | FPR2 (0.39) | FPR2HTR2CHTR2BNOS3NOS1 | |
| SCHEMBL4300912 | 0.79 | HSD11B1 (0.34) | NOS3NOS1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | RIBON THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| CN-114761086-A | Pyridazinones as PARP7 inhibitors | 里邦医疗公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-05-06 | — | — | US | disclosed |
| WO-2021087025-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130342-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | FPR2 2873/4885HTR2C 1340/4885HTR2B 978/4885 |
| US-11691969-B2 | Pyridazinones as PARP7 inhibtors | PARP2, PARP1, PARP4 | FPR2 4408/4885HTR2C 1044/4885HTR2B 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.